Ali­gos crum­bles af­ter ax­ing lead as­set, as an­a­lysts rue an­oth­er flop in 'beat­en-down' sec­tor

Ali­gos Ther­a­peu­tics took a beat­ing Thurs­day af­ter re­port­ing it is stop­ping de­vel­op­ment on its lead pro­gram for chron­ic he­pati­tis B.

The biotech’s shares $AL­GS closed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER